Royalty pharma plc RPRX 深 沪
等待开盘 08-01 09:30:00 美东时间
36.80
-0.320
-0.86%
华盛通- 最 高37.55
- 今 开37.09
- 成交量 215.92万股
- 最 低 36.71
- 昨 收 37.12
- 总市值 154.93亿
- 52周最高 37.565
- 市盈率 静 19.25
- 换手率 0.51%
- 52周最低 23.61
- 委 比 19.92%
- 总股本 4.21亿
- 历史最高 52.68
- 量 比 0.95
- 振 幅 2.26%
- 历史最低 23.61
- 每 手 1
- 风险率 1.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Royalty Pharma declares $0.22 dividend
Royalty Pharma (NASDAQ:RPRX) declared $0.22/share quarterly dividend, in line with previous. Forward yield 2.48% Payable Sept. 10; for shareholders of record Aug. 15; ex-div Aug. 15. See RPRX Dividend...
07-18 20:19
Royalty Pharma Declares Third Quarter 2025 Dividend
The board of directors of Royalty Pharma plc has approved a dividend of $0.22 per Class A ordinary share for the third quarter of 2025. The dividend will be paid on September 10, 2025, to shareholders of record as of August 15, 2025. Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector, collaborating with a range of entities from academic institutions t...
07-18 12:15
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
<p>Royalty Pharma announced the appointment of Carole Ho and Bess Weatherman to its Board of Directors. This strengthens independent representation on the board to over 90%, reflecting the company's commitment to improved corporate governance following its acquisition of an external manager. Carole Ho, with 20 years of experience in biopharma, brings expertise in therapeutic development, while Bess Weatherman, a veteran investor with 35 years in ...
07-17 12:15
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
Royalty Pharma plc将于2025年8月6日发布2025年第二季度财务报告，并于当天东部时间上午8点举行网络直播。公司成立于1996年，专注于生物制药特许权使用费的购买和创新资助，与各类机构和药企合作，拥有包括Vertex的Trikafta、GSK的Trelegy等在内的35款商业化产品和16款开发阶段候选产品。更多信息可访问其投资者页面。
07-16 20:15
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Morgan Stanley Maintains Overweight on Royalty Pharma, Raises Price Target to $54
Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $51 to $54.
07-11 00:17
Revolution Medicines dips 5%, gets $2B flexible funding
A late-stage clinical oncology company, Revolution Medicines (NASDAQ:RVMD) partnered with Royalty Pharma on $2B in flexible funding to support its product development and commercialization for its p...
06-24 19:36
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
Royalty Pharma announces a $2 billion funding partnership with Revolution Medicines, including up to $1.25 billion in synthetic royalty financing and $750 million in secured debt. This supports the global development and commercialization of daraxonrasib, a RAS(ON) inhibitor in Phase 3 for pancreatic cancer and NSCLC, targeting all major RAS mutations. Royalty Pharma's flexible funding allows Revolution Medicines to retain control over its pipeli...
06-24 11:05
A Look Into Royalty Pharma Inc's Price Over Earnings
In the current market session, Royalty Pharma Inc. (NASDAQ:RPRX) stock price is...
06-23 23:00
